Literature DB >> 6376145

Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.

A J Scheen, P J Lefebvre, A S Luyckx.   

Abstract

Peripheral blood glucose, plasma insulin and C-peptide levels were investigated after giving a standardized breakfast (500 kcal, 60 g carbohydrates) to 10 nonobese Type 2 diabetic patients previously treated by diet alone. Each patient received at random, at 1 week intervals, either 5 mg glipizide (meal + glipizide) or a placebo (meal alone) 30 min before breakfast. Basal values of blood glucose, plasma insulin and C-peptide were similar on both occasions. After meal + glipizide, the blood glucose increase was sharply limited whereas the rise in plasma insulin was steeper and reached twice as high a level. In contrast, the rise in plasma C-peptide was similar in both conditions. Consequently, the areas under the curves (0-300 min) showed a marked reduction in blood glucose after meal + glipizide (2289 +/- 149 versus 3101 +/- 169 mmol X min/1; 2p less than 0.001), associated with a significant increase in plasma insulin (14219 +/- 3261 versus 7591 +/- 1173 microU X min/ml; 2p less than 0.025) but no significant change in plasma C-peptide (342 +/- 45 versus 326 +/- 34 pmol X min/ml; N.S.). The insulin/C-peptide molar ratio was thus significantly increased after meal + glipizide (0.41 +/- 0.06 versus 0.23 +/- 0.04 at the 60th min; 2p less than 0.02). The dissociation between the responses of insulin and C-peptide suggests that a single dose of 5 mg glipizide in Type 2 diabetic subjects may enhance availability of peripheral insulin by extrapancreatic mechanism(s). This phenomenon may result in a higher circulating level of the hormone and therefore represent a further mode of action of sulphonylureas.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376145     DOI: 10.1007/bf00542143

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

2.  Comparison of plasma insulin levels following administration of tolbutamide and glucose.

Authors:  R S YALOW; H BLACK; M VILLAZON; S A BERSON
Journal:  Diabetes       Date:  1960 Sep-Oct       Impact factor: 9.461

3.  Immunoreactive insulin in portal and hepatic venous blood in patients with insuloma.

Authors:  M Eriksson; R Erwald; R Hed; A Nygren; J Patricny; S Röjdmark; L Sundblad; K L Wiechel
Journal:  Acta Med Scand       Date:  1976

4.  Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients.

Authors:  G Sartor; B Scherstén; A Melander
Journal:  Acta Med Scand       Date:  1978

Review 5.  Appraisal of the extrapancreatic actions of sulfonylureas.

Authors:  J M Feldman; H E Lebovitz
Journal:  Arch Intern Med       Date:  1969-03

6.  Hepatic effect of sulfonylureas.

Authors:  A Marshall; R L Gingerich; P H Wright
Journal:  Metabolism       Date:  1970-12       Impact factor: 8.694

7.  The breakfast tolerance test: a return to physiology.

Authors:  P J Lefebvre; A S Luyckx
Journal:  Diabete Metab       Date:  1976-03

8.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

9.  Insulin in portal, hepatic and peripheral venous blood after glucose, tolbutamide and glipizide stimulation. Indication of insulin release from peripheral tissues.

Authors:  R Hed; A Nygren; R Röjdmark; L Sundblad; K L Wiechel
Journal:  Acta Med Scand       Date:  1979

10.  Long term improvement in insulin response with gliclazide treatment.

Authors:  H J Bodansky; S Medback; A G Cudworth; L H Rees; R S de Silva
Journal:  Diabete Metab       Date:  1982-12
View more
  10 in total

1.  Extrapancreatic insulin effect of glibenclamide.

Authors:  H Mulder; W Schopman; A J van der Lely
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin.

Authors:  N Barzilai; P H Groop; L Groop; R A DeFronzo
Journal:  Acta Diabetol       Date:  1995-12       Impact factor: 4.280

Review 3.  Sulfonylureas: a new look at old therapy.

Authors:  Peter M Thulé; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

Review 4.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

5.  Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM).

Authors:  A E Pontiroli; M G Perfetti; G Pozza
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion.

Authors:  G Sartor; D Ursing; P Nilsson-Ehle; E Wåhlin-Boll; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus.

Authors:  P O Bitzén; A Melander; B Scherstén; M Svensson; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Management of non-insulin-dependent diabetes mellitus.

Authors:  P J Lefèbvre; A J Scheen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

Authors:  A Melander; P O Bitzén; O Faber; L Groop
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

10.  Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.

Authors:  Takahiro Abe; Yasuhiro Matsubayashi; Sayaka Muragishi; Akihiro Yoshida; Hideki Suganami; Kenichi Furusawa; Kazuya Fujihara; Shiro Tanaka; Kohei Kaku; Hirohito Sone
Journal:  J Diabetes Investig       Date:  2021-05-26       Impact factor: 4.232

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.